Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics

Abstract

Background: Proposals for population screening for genetic diseases require careful scrutiny by decision makers because of the potential for harms and the need to demonstrate benefits commensurate with the opportunity cost of resources expended. Methods: We review current evidence-based processes used in the United States, the United Kingdom, and the Netherlands to assess genetic screening programs, including newborn screening programs, carrier screening, and organized cascade testing of relatives of patients with genetic syndromes. In particular, we address critical evidentiary, economic, and ethical issues that arise in the appraisal of screening tests offered to the population. Specific case studies include newborn screening for congenital adrenal hyperplasia and cystic fibrosis and adult screening for hereditary hemochromatosis. Results: Organizations and countries often reach different conclusions about the suitability of screening tests for implementation on a population basis. Deciding when and how to introduce pilot screening programs is challenging. In certain cases, e.g., hereditary hemochromatosis, a consensus does not support general screening although cascade screening may be cost-effective. Conclusion: Genetic screening policies have often been determined by technological capability, advocacy, and medical opinion rather than through a rigorous evidence-based review process. Decision making should take into account principles of ethics and opportunity costs.

Women’s and health professionals’ preferences for prenatal tests for Down syndrome: a discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests

“…37,38 Ideally, the implementation of NIPD will take all stakeholder views into consideration. Furthermore, health professionals must recognize that their views about prenatal tests may differ from those of the women with whom they discuss testing.…”

The Klinefelter syndrome: current management and research challenges

“…Therefore, before a general program for all neonates is initiated, the merit of such screening should be explored in well-conducted investigations of defined populations. In general, one can consider populationbased genetic screening if a condition is an important health problem with a latent early symptomatic stage, has a wellunderstood natural history, and there exist accepted treatments with associated facilities for providing diagnosis and treatment (Grosse et al, 2009). These requirements are fulfilled by KS to some extent, but a formal proof of improved long-term adult outcomes is lacking.…”

Genome-wide association studies: a powerful tool for neurogenomics

“…48,49 The clinical utility of genetic testing has been difficult to demonstrate for a variety of reasons, but significant effort is currently being expended to overcome these obstacles. Single-nucleotide polymorphisms implicated in the most powerful GWA studies typically explain only a small fraction of the observed variation for a disease, which partly stems from a combination of methodological and practical limitations.…”